Condition: Relapsed/Refractory T-cell Lymphoma · Relapsed/Refractory Acute Myeloid Leukemia · Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
CD70 is a promising target for immunotherapy because it is overexpressed in T-cell lymphoma (TCL) and acute myeloid leukemia (AML) tumor cells but is found in deficient levels in normal tissues and hematopoietic stem cells. This study aims to evaluate the safety and efficacy of CD70-targeted CAR-NK (CD70-CAR-NK) cells in patients with relapsed and refractory TCL and AML.
This description comes directly from the study's public registry record.
Wenbin Qian · +86 0571 87783759 · qianwb@zju.edu.cn
Yang Xu, Ph.D · yxu@zju.edu.cn
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06696846